Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.39 USD
-0.46 (-3.88%)
Updated May 24, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DVAX 11.39 -0.46(-3.88%)
Will DVAX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DVAX
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
Other News for DVAX
Unveiling Dynavax Technologies (DVAX)'s Value: Is It Really Priced Right? A Comprehensive Guide
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Hold Rating on Dynavax Amidst FDA Setback and Long-term Profitability Focus
Analysts’ Top Healthcare Picks: aTyr Pharma (LIFE), Dynavax (DVAX)